Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) International — Organic / Comparable Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q4 2025
8.3%
Period ended Dec 31, 2025
Change on a year earlier
-2.4 pts
10.7% in Q4 2024
History
40 quarters
Since Q4 2015
Sources
40
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) International — Organic / Comparable Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | 8.3% | -2.4 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | 7.7% | +6.4 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | -12.1% | -26.6 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | 7.3% | +8.1 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | 10.7% | +13.6 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | 1.3% | -19.1 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | 14.5% | -0.7 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | -0.8% | – | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | -2.9% | -17.3 pts | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | 20.4% | +15.1 pts | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | 15.2% | +14.9 pts | SEC Filing (0001628280-23-025156) ↗ |
| Q4 2022 | Dec 31, 2022 | 14.4% | +10.5 pts | SEC Filing (0001628280-23-001516) ↗ |
| Q3 2022 | Sep 30, 2022 | 5.3% | +5.4 pts | SEC Filing (0001628280-22-026588) ↗ |
| Q2 2022 | Jun 30, 2022 | 0.3% | +6.2 pts | SEC Filing (0001104659-22-081006) ↗ |
| Q1 2022 | Mar 31, 2022 | 3.8% | 0.0 pts | SEC Filing (0001104659-22-047560) ↗ |
| Q4 2021 | Dec 31, 2021 | 3.9% | -8.4 pts | SEC Filing (0001104659-22-007648) ↗ |
| Q3 2021 | Sep 30, 2021 | -0.1% | -9.9 pts | SEC Filing (0001104659-21-127874) ↗ |
| Q2 2021 | Jun 30, 2021 | -5.9% | -34.9 pts | SEC Filing (0001104659-21-094680) ↗ |
| Q1 2021 | Mar 31, 2021 | 3.8% | -30.5 pts | SEC Filing (0001104659-21-052205) ↗ |
| Q4 2020 | Dec 31, 2020 | 12.3% | -5.1 pts | SEC Filing (0001104659-21-007942) ↗ |
| Q3 2020 | Sep 30, 2020 | 9.8% | +4.2 pts | SEC Filing (0001104659-20-116611) ↗ |
| Q2 2020 | Jun 30, 2020 | 29.0% | +22.1 pts | SEC Filing (0001104659-20-083929) ↗ |
| Q1 2020 | Mar 31, 2020 | 34.3% | +47.4 pts | SEC Filing (0001104659-20-047187) ↗ |
| Q4 2019 | Dec 31, 2019 | 17.4% | +16.3 pts | SEC Filing (0001104659-20-005717) ↗ |
| Q3 2019 | Sep 30, 2019 | 5.6% | -3.0 pts | SEC Filing (0001104659-19-054283) ↗ |
| Q2 2019 | Jun 30, 2019 | 6.9% | -2.8 pts | SEC Filing (0001104659-19-040664) ↗ |
| Q1 2019 | Mar 31, 2019 | -13.1% | -31.7 pts | SEC Filing (0001104659-19-021809) ↗ |
| Q4 2018 | Dec 31, 2018 | 1.1% | +4.8 pts | SEC Filing (0001104659-19-002848) ↗ |
| Q3 2018 | Sep 30, 2018 | 8.6% | -8.1 pts | SEC Filing (0001104659-18-062380) ↗ |
| Q2 2018 | Jun 30, 2018 | 9.7% | -3.0 pts | SEC Filing (0001104659-18-045642) ↗ |
| Q1 2018 | Mar 31, 2018 | 18.6% | +9.9 pts | SEC Filing (0001104659-18-024701) ↗ |
| Q4 2017 | Dec 31, 2017 | -3.7% | -40.9 pts | SEC Filing (0001104659-18-003691) ↗ |
| Q3 2017 | Sep 30, 2017 | 16.7% | +2.6 pts | SEC Filing (0001104659-17-062667) ↗ |
| Q2 2017 | Jun 30, 2017 | 12.7% | -4.7 pts | SEC Filing (0001104659-17-045904) ↗ |
| Q1 2017 | Mar 31, 2017 | 8.7% | +1.5 pts | SEC Filing (0001104659-17-024344) ↗ |
| Q4 2016 | Dec 31, 2016 | 37.2% | +37.6 pts | SEC Filing (0001104659-17-003920) ↗ |
| Q3 2016 | Sep 30, 2016 | 14.1% | – | SEC Filing (0001104659-16-150813) ↗ |
| Q2 2016 | Jun 30, 2016 | 17.4% | – | SEC Filing (0001104659-16-133433) ↗ |
| Q1 2016 | Mar 31, 2016 | 7.2% | – | SEC Filing (0001104659-16-112689) ↗ |
| Q4 2015 | Dec 31, 2015 | -0.4% | – | SEC Filing (0001104659-16-091861) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) International — Organic / Comparable Sales Growth (%) (%), quarterly Q4 2015–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-poc-leg-yoy-org-intl
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.